Tech Company Financing Transactions
Courage Therapeutics Funding Round
Courage Therapeutics, based in Ann Arbor, secured investment capital from Arsenal Venture Partners and private investors.
Transaction Overview
Company Name
Announced On
11/3/2025
Transaction Type
Venture Equity
Amount
Unknown
Round
Seed
Investors
Arsenal Venture Partners (Lead Investor)
Proceeds Purpose
The company intends to use the funds to expand operations and its development efforts.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Undisclosed
Ann Arbor, MI Undisclosed
USA
Ann Arbor, MI Undisclosed
USA
Phone
Undisclosed
Website
Email Address
Overview
Courage Therapeutics is a leading neuroendocrine company co-founded by Dr. Roger Cone, a pioneering researcher in melanocortin receptor biology and the central melanocortin system's neural circuits in the brain. The company is dedicated to translating Dr. Cone's decades of work and discoveries of novel biological mechanisms of energy homeostasis into novel therapeutic candidates targeting the MC4R and MC3R receptors.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Giovanni Ferrara
Browse more venture capital transactions:
Prev: 11/3/2025: i6 venture capital transaction
Next: 11/3/2025: mimic robotics venture capital transaction
Share this article
News on VC Transactions
We do our best to report on funding rounds that are announced publicly. VC investment data records reported here are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs